Table 2.
EBV viral profile, pathological, immunophenotypic and clonality study findings
| Case | Category@ | EBV | Phenotype | TCR clonality | Treatment | Outcome (m) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| VCA-IgM | VCA-IgG | EA | EBNA | Viral load# | EBER | ||||||
| 1 | NA | + | + | NA | NA | NA | NA | Cytotoxic T | Clonal | Supportive | NED (10) |
| 2 | NA | NA | NA | NA | NA | +* | NA | Cytotoxic T | Clonal | Supportive & antibiotics | NED (28) |
| 3 | NA | + | + | - | - | NA | + (LN: 10%) | Cytotoxic T | Polyclonal | Supportive & antibiotics | NED (13) |
| 4 | NA | NA | NA | NA | NA | 375/ml | + (BM & liver: 1%) | Cytotoxic T | Polyclonal | Etoposide & prednisolone | NED (14) |
| 5 | NA | NA | + | - | - | NA | + (LN 5%) | Cytotoxic T | Polyclonal | Supportive | NED (4) |
| 6 | A1 | - | + | - | + | 8,497 | + (LN 5%) | Helper T | Polyclonal | Supportive | NED (4) |
| 7 | A1 | - | + | NA | NA | NA | + (LN: 30%) | Cytotoxic T | Polyclonal | IVIG & prednisolone; then immunochemotherapy* | NED (31) |
| 8 | A2 | - | + | - | + | 3,623, 6,160, 13,781 | + (LN: 30%) | Helper T | Clonal | Prednisolone | AWD (51) |
| 9 | A3 | - | + | + | + | 210 | + (BM: 90%; liver: 30%) | Cytotoxic T | Poor DNA | Chemotherapy | DOD (31) |
| 10 | B | - | NA | NA | NA | 56,8324 | + (BM) | CD4/CD8 double negative | Polyclonal (poor DNA for study) | ESHAP | DOD (3) |
#
The EBV viral load was presented as copies number/ml with sequential testing results listed for Case 8.
@
Pathological categorization of EBV-associated T/NK LPD according to Ohshima et al. [5].
*
Immunochemotherapy regimen for Case 7 included prednisolone, cyclosporine and etoposide.
Abbreviations: CAEBV, chronic active EBV infection; Dx, diagnosis; EA, early antigen; EBER, in situ hybridization for EBV-encoded mRNA; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; IVIG, intravenous immunoglobulin; NA, not available; NED, no evidence of disease; TCR, T-cell receptor gene rearrangement; VCA, viral capsid antigen.